Pay in 4 interest-free payments of $7.00 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
The supply agreement is designed to support the evaluation of Immuneerings lead candidate, atebimetinib (IMM-1-104), a novel dual MEK inhibitor, in combination with olomorasib in a planned Phase II trial in patients with locally advanced or metastatic KRAS G12c-mutant non-small cell lung cancer (NSCLC) who have progressed on prior therapy
The lightweight, fast-absorbing formula is suitable for use under makeup and can be incorporated into both your morning and evening skincare routines
Abdalla, Rahma H
Injection-Site Reactions Possible reactions may include redness, tenderness, itching, bruising, irritation or swelling near the injection area
Patients who qualify for weight loss treatment today can access semaglutide or tirzepatide now
US$ 25.28
US$ 29.76
US$ 29.22
US$ 24.16
